Contemporary pharmacotherapy for familial hypercholesterolemia in children and adolescents.
文献摘要
Introduction Familial hypercholesterolemia (FH) elevates low-density lipoprotein cholesterol (LDL-C) from birth, accelerating early atherosclerosis and offering an opportunity for prevention in childhood. Areas covered This review addresses diagnosis and treatment of heterozygous and homozygous FH in children and adolescents, covering statins, ezetimibe, PCSK9 monoclonal antibodies, inclisiran, bile acid sequestrants, bempedoic acid, evinacumab, lomitapide, and lipoprotein apheresis. Pediatric dosing, efficacy, safety, vascular effects, follow-up, and recommendations are evaluated. Sources include PubMed/MEDLINE publications through September 2026, guidelines, consensus statements, and FDA/EMA information. Expert opinion Statins remain first-line therapy, but LDL-C targets often require early combination treatment to minimize lifelong exposure. Evidence is strongest for short-term lipid lowering and statin safety; outcome trials are impractical, and long-term data for newer drugs remain limited. Registries should assess sustained safety, adherence, development, imaging, and cardiovascular outcomes. Underdiagnosis and unequal access remain major barriers. Screening with cascade testing, genotype-informed treatment, long-acting PCSK9-directed therapies, and LDL receptor-independent approaches for homozygous FH will likely shape care. Earlier diagnosis and prompt treatment intensification should prioritize preventing atherosclerosis onset.